key: cord-0690409-58r5wcwd
authors: Raman, Betty; Bluemke, David A.; Lüscher, Thomas F.; Neubauer, Stefan
title: Long COVID: post-acute sequelae of COVID-19 with a cardiovascular focus
date: 2022-02-18
journal: Eur Heart J
DOI: 10.1093/eurheartj/ehac031
sha: 90f63f3b272675201f765504c0ff4618f92fc46f
doc_id: 690409
cord_uid: 58r5wcwd

Emerging as a new epidemic, long COVID or post-acute sequelae of coronavirus disease 2019 (COVID-19), a condition characterized by the persistence of COVID-19 symptoms beyond 3 months, is anticipated to substantially alter the lives of millions of people globally. Cardiopulmonary symptoms including chest pain, shortness of breath, fatigue, and autonomic manifestations such as postural orthostatic tachycardia are common and associated with significant disability, heightened anxiety, and public awareness. A range of cardiovascular (CV) abnormalities has been reported among patients beyond the acute phase and include myocardial inflammation, myocardial infarction, right ventricular dysfunction, and arrhythmias. Pathophysiological mechanisms for delayed complications are still poorly understood, with a dissociation seen between ongoing symptoms and objective measures of cardiopulmonary health. COVID-19 is anticipated to alter the long-term trajectory of many chronic cardiac diseases which are abundant in those at risk of severe disease. In this review, we discuss the definition of long COVID and its epidemiology, with an emphasis on cardiopulmonary symptoms. We further review the pathophysiological mechanisms underlying acute and chronic CV injury, the range of post-acute CV sequelae, and impact of COVID-19 on multiorgan health. We propose a possible model for referral of post-COVID-19 patients to cardiac services and discuss future directions including research priorities and clinical trials that are currently underway to evaluate the efficacy of treatment strategies for long COVID and associated CV sequelae.

The crippling effect of coronavirus disease 2019 (COVID-19) on healthcare and economies globally has undoubtedly been one of the worst disasters experienced by humans in the last decades. Worldwide, survivors of COVID-19 now exceed hundreds of millions, 1 with some reporting incomplete recovery months beyond the acute illness, a condition commonly referred to as long COVID. Persistent symptoms of breathlessness, chest pain, fatigue, headaches, brain fog, and palpitations are a constant reminder of the devastation caused by this virus and the need to remain vigilant for any long-term damage. Now, more than ever before, management of cardiometabolic risk factors should become a priority for physicians, as their formidable power in intensifying COVID-19 illness severity has been convincingly documented. The long-term impact of COVID-19 on cardiovascular (CV) health and mortality is also emerging as a major global concern.

In this review, we discuss the definition of long COVID, epidemiology of cardiopulmonary manifestations in the context of long COVID, pathophysiological mechanisms for acute and chronic cardiac injury secondary to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, its management, and future directions.

The term 'long COVID' was originally coined by a patient 2,3 and asserts the notion that suffering does not stop with resolution of acute infection. While there is no universally accepted definition, in December 2020 the United Kingdom (UK) National Institute for Health and Care Excellence guidelines 4 defined long COVID as persistence of symptoms beyond 4 weeks of SARS-CoV-2 infection. This term comprises two phases: ongoing symptomatic phase (4-12 weeks) and post-COVID-19 syndrome (.12 weeks) based on the duration of symptoms. More recently, the World Health Organization provided a case definition for post-COVID-19 condition, 5 a term used to refer to persistence of symptoms beyond 3 months of SARS-CoV-2 infection, lasting for at least 2 months and not explained by any other illness. Other terms used to describe long COVID include post-acute COVID-19 syndrome, 6 post-acute sequelae of COVID-19, 7 and long-haul COVID. 8 Long COVID is a vacillating disease, 9 characterized by a diverse range of symptoms spanning multiple organ systems, as depicted in Figure 1 and Graphical Abstract, and commonly includes fatigue, breathlessness, post-exertional malaise (PEM), brain fog, headaches, nausea, vomiting, anxiety, depression, skin rash, joint pain, and palpitations. Patient advocacy groups 6 (e.g. long COVID SOS, COVID Advocacy Exchange, the National Patient Advocate Foundation COVID Care Resource Center, long-haul COVID fighters, Body Politic COVID-19 Support Group) have enhanced our understanding of this disease by drawing our attention to its multifaceted nature. Several experts 10, 11 have noted its marked similarities with other post-viral symptoms (e.g. Epstein-Barr, 12 human herpesvirus, 13 influenza, SARS, 14 and Ebola viruses 15 ), although few options exist for the management of such syndromes.

The reported prevalence of long COVID has varied across and within many countries: UK 1.6-71%, [16] [17] [18] [19] Germany 35-77%, 20, 21 China 49-76%, 22, 23 Africa 68%, 24 India 22%, 25, 26 Bangladesh 16-46%, 27, 28 Denmark 1%, 29 Italy 5-51%, 30 ,31 USA 16-53%, 32, 33 Norway 61%. 34 Studies assessing hospitalized patients have typically reported higher prevalence estimates (e.g. 76% in Huang et al., 22 71% in Evans et al. 19 ) when compared with community studies (e.g. Sudre et al. 16 ), reflecting the complex relationship between severity of acute illness, higher burden of co-morbidities, and persistent symptoms. Differences in the study population may explain the vast disparity in prevalence estimates across the various studies. The timing of assessment also appears to be important as symptom frequency can diminish over time from the infection. Hossain et al. 28 reported a reduction in the burden of long COVID symptoms which affected 21.2% of their cohort at 4 weeks and 16.5% by 12 weeks post-COVID diagnosis. A similar temporal improvement in symptom burden was also observed by Wu et al. 35 and Cassar et al. 36 Varying definitions of long COVID may also affect the relative frequencies. Mahmud et al. 27 defined long COVID as the persistence of symptoms beyond 2 weeks (i.e. time taken for viral clearance) and reported a symptom prevalence of 46%. In contrast, more conservative definitions such as the one used by the UK Office of National Statistics (requiring the presence of functional limitation and exclusion of symptoms explained by comorbidities) have resulted in lower prevalence estimates. The study design is also likely to be relevant as retrospective reporting from electronic healthcare records suffers from ascertainment bias, while prospective studies with comprehensive assessments 37 are likely to attract patients with a high burden of symptoms seeking an explanation. In addition to these, disparities in vaccinations, SARS-CoV-2 variants, co-morbidities, study sample size, and use of varying non-COVID control groups appear to drive heterogeneity in prevalence estimates, as illustrated in Figure 2 .

Contrary to the variability seen in reported disease prevalence, risk factors for long COVID tend to be fairly consistent, with female sex, escalating age, obesity, asthma, poor general health, poor prepandemic mental health, poor sociodemographic factors emerging as important determinants across several studies. [16] [17] [18] [38] [39] [40] In particular, the impact of nationwide lockdowns, remote working, and limited physical activity on pre-existing trends of an increasingly obese population with poor dietary intake and physical activity patterns is noteworthy. [41] [42] [43] According to national statistics data from the UK (from 2019), 44 among adults 16 and over, a staggering 68% of men and 60% of women were either overweight or obese. Obesity increased across all age groups up to 75 years old. In a separate report by the national child measurement programme from the UK, one in three children leaving primary school were noted to be overweight or obese and one in five obese in 2019. 45 A recent update from the American Heart Association (AHA) 46 on stroke and CV disease has also highlighted the high prevalence of obesity, metabolic syndrome, poor dietary habits, and physical inactivity among children and adults from the US. It is now well established that obesity and other cardiometabolic risk factors commonly promote inflammation and endothelial dysfunction, 47, 48 which may lower the cardiometabolic reserve and threshold for exertional symptoms. Consistent with this, numerous population and prospective cohort studies have documented an independent link between obesity and long COVID. 16, 19, 38 Thompson et al., 38 in a prospective study of 6907 patients (mean age 19-63 years), reported that being overweight or obese was associated with a 25% higher likelihood of long COVID than not belonging to this category. Similarly, Sudre et al. 16 reported that patients with prolonged symptoms were more likely to be obese than those without.

Cardiopulmonary symptoms including chest pain, dyspnoea, fatigue, palpitations, and cough are common among long haulers. In one UK study, 16 13 .3% of 4182 symptom app users (predominantly community patients) experienced at least one persistent symptom beyond 4 weeks of infection, of which half were thought to be cardiac in origin. In December 2020, the UK ONS 49 provided similar estimates of long COVID prevalence, though a recent Figure 1 Long COVID is characterized by a diverse range of symptoms and signs spanning multiple organ systems including the respiratory system, neurological system, cardiovascular system, gastrointestinal system, dermatological system, endocrine/genitourinary systems, and skeletal muscle/joints as illustrated here. PTSD, post-traumatic stress disorder.

Long COVID/post-acute sequelae of analysis with a stricter case definition (symptoms explained by comorbidities were not counted) by the ONS 18,50 and other groups 29 suggests lower prevalence estimates (1.2-1.5%). Patient-led or survey-based research from long COVID support groups 37,51 has also provided insights into the longitudinal trajectory of persistent symptoms. In an international online survey study undertaken by Davis et al. 37 of 3762 patients, cardiac symptoms including chest pain ( 53%), palpitations ( 68%), fainting ( 13%) were observed in up to 86% of patients by 7 months from infection. Postural orthostatic tachycardia syndrome (POTS), characterized by an increase in heart rate of at least 30 b.p.m. from supine to standing position, was noted in 31% of patients. 52 Ziauddeen et al. 51 similarly studied the prevalence of long COVID among 2550 patients using a social media survey. Cardiopulmonary symptoms were reported by 89% of participants in their study.

There are now several prospective follow-up studies of hospitalized patients. One of the earliest published reports of long COVID came from an Italian study of hospitalized patients by Carfi et al., 53 demonstrating a particularly high burden of cardiopulmonary symptoms (.43%). In a subsequent follow-up study of 1733 hospitalized patients from Wuhan, China, Huang et al. 22 observed that at 6 months post-infection, 63% of patients reported fatigue, 26% breathlessness, and 5-9% experienced chest pain and palpitations. By 12 months, 23 investigators of the same study showed that symptoms of breathlessness (30%) and chest pain (7%) were slightly more common, while fatigue had improved (20%). Evans et al. 19 from the UK also undertook a follow-up study of 1077 hospitalized patients. At a median of 5 months postdischarge, 48% reported persistent fatigue, 41% dyspnoea, and 21-28% chest pain and palpitations.

Long COVID has been proposed to be a form of chronic fatigue syndrome (CFS)/myalgic encephalitis. 52 While there are marked similarities between the two, subtle yet important differences exist. Central to the diagnosis of CFS is the observation that patients experience PEM, 54,55 defined as fatigue following even minor physical or mental exertion. For a diagnosis of CFS, symptoms should last for a minimum of 6 months and occur at least 50% of the time. Current definitions of long COVID do not obligate the presence of Figure 2 Factors that contribute to variability in prevalence estimates of long COVID. Prevalence estimates of long COVID are highly variable across studies due to a number of factors that introduce bias. These include differences in cohort characteristics, age, and sex of subjects enrolled, timing of assessment, sociodemographic factors, vaccines and variants, pre-existing health problems, sample size, study design, and variability in questionnaires or tools used. HCW, healthcare workers; m, months; PCR, polymerase chain reaction; wks, weeks. PEM, with symptom duration yet to be defined. A further point to note is that, while the evidence for exercise rehabilitation in CFS patients is mixed, early positive data supporting tailored rehabilitation in previously hospitalized patients with long COVID are emerging with some improvement seen in exercise capacity and cognition at 4 months from discharge. 56 Finally, breathlessness, one of the most common long COVID symptom, is not essential for the diagnosis of CFS and may be due to distinct mechanisms. Nonetheless, the similarities between CFS and long COVID are striking, with both syndromes having links to psychological and neurostructural/metabolic alterations 57-59 (e.g. grey matter volume reduction in the limbic cortex in post-COVID patients 60 ), highlighting the potential benefits of neuroprotective interventions in such patients.

Given the abundance of cardiac symptoms among patients with long COVID, a deeper discussion of potential mechanisms underlying cardiac injury is warranted.

The role of angiotensin-converting enzyme 2 receptors in SARS-CoV-2 involvement of the heart is now well established. Several mechanisms have been proposed to contribute to myocardial injury including direct cytotoxic injury, 1 dysregulation of renin-angiotensin-aldosterone system, 3 endotheliitis and thromboinflammation, and 4 dysregulated immune response with cytokine release. 6 

The pattern of myocardial injury following SARS-CoV-2 infection derived from autopsy studies suffers from referral bias but has provided initial pathophysiological clues. In an early autopsy series of 80 consecutive SARS-CoV-2 PCR positive cases, 61 only four patients (5%) had suspected cardiac injury. Two patients had co-morbid conditions and died of sudden cardiac death. One had acute myocardial infarction and another exhibited right ventricular lymphocytic infiltrates. These early results suggested that extensive myocardial injury as a primary cause of death may be infrequent.

In a subsequent multicentre autopsy study, Basso et al. 62 characterized the hearts in 21 selected autopsies. Myocarditis (defined as lymphocytic infiltration and myocyte necrosis) was evident in 14% of cases, interstitial macrophage infiltration in 86%, and pericarditis and right ventricular injury in 19%, respectively. Halushka and Vander Heide 63 performed a review of 22 publications describing the autopsy results of 277 patients. Lymphocytic myocarditis was reported in 7.2%; however, only 1.4% met the well-established histological criteria 64 for myocarditis, suggesting that true myocarditis was rare. [65] [66] [67] In another study, Lindner et al. 68 demonstrated the presence of SARS-CoV-2 viral particles in the hearts of 24/39 (59%) consecutive autopsies; the viral load was clinically relevant in 16/39 (41%). Of note, viral particles were not isolated within cardiomyocytes, but rather in interstitial cells including pericytes and macrophages. The high viral load in some cases was also not associated with inflammation, consistent with the low prevalence of myocarditis on autopsy studies. 67 Microvascular injury due to SARS-CoV-2

Cardiac troponin levels are frequently elevated in COVID-19 patients, 69 indicating myocardial injury and/or ischaemia. The work of Bois et al. 70 appears to support the concept of microthrombi occurring in association with COVID-19. In a small series of 15 individuals, the authors observed that post-mortem fibrin microthrombi were more common (80%) than acute ischaemic injury (13%) and myocarditis (33%) suggesting a role for thrombosis in accentuating myocardial injury.

Fox and Vander Heide 65 have conceptualized the array of pathophysiological mechanisms underlying myocardial injury. The authors proposed that hypoxia and pulmonary microvascular damage may lead to right heart stress and myocyte necrosis. The latter may be further augmented through localized microvascular effects, endotheliitis, 71 associated microthrombi, and altered renin-angiotensin homeostasis. 72 Elevated cytokines 73, 74 [e.g. interleukins (IL)-1, IL-16, IL-17, IL-22, interferon (IFN)-γ, tumour necrosis factor (TNF)-α] could also contribute to myocardial injury by inducing endothelial dysfunction, activation of platelets, recruitment of neutrophils, and eventually triggering a hypercoagulable state. In this framework, viral myocarditis would play an infrequent role in SARS-CoV-2 infection.

Mechanisms for enduring cardiac damage post-acute illness are still poorly understood. One possible explanation is a chronic inflammatory response evoked by persistent viral reservoirs in the heart following the acute infection, 75 which may, in turn, be exacerbated by obesity-related inflammatory signalling driven in part by perivascular adipose tissue via the release of adipokines such as monocyte chemoattractant protein-1 and Regulated upon Activation, Normal T Cell Expressed, and Presumably Secreted, chemokines that aggravate endothelial dysfunction via endothelial nitric oxide synthetase uncoupling and reactive oxygen species production. 76 An unintended consequence of such processes would be insidious tissue damage, followed by chronic myocardial fibrosis leading to impaired ventricular compliance, impaired myocardial perfusion, increased myocardial stiffness, reduced contractility and potential arrhythmias.

A second mechanism for delayed damage is an autoimmune response to cardiac antigens through molecular mimicry. 77 High-throughput proteome analysis by Wang and others [78] [79] [80] has identified a range of autoantibodies to humoral and tissue antigens in patients with severe COVID-19. Autoantibodies to cholinergic and adrenergic receptors have also been detected in individuals with CFS. 81, 82 Recently, a number of longitudinal cytokine profiling and proteomic studies 83, 84 have revealed an increased expression of prothrombotic factors (e.g. factor VIII, prothrombin, plasminogen activator inhibitor-1) beyond the acute infection. This is in keeping with the burgeoning reports of delayed embolic complications. [85] [86] [87] The high prevalence of pulmonary vascular thrombosis (5-30%), 87, 88 particularly in hospitalized patients, is also expected to heighten the future risk of chronic Long COVID/post-acute sequelae of COVID-19 thrombo-embolic pulmonary hypertension. 89 Endothelial dysfunction 90 and its complications may also develop in patients, with evidence of persistent impairment detected in younger individuals 3-4 weeks after SARS-CoV-2 infection. 91 The Graphical Abstract summarizes the relevant pathophysiological mechanisms for acute and chronic cardiac injury secondary to SARS-CoV-2 infection and potential long-term consequences. It is worth noting that many of these complications mirror those encountered by survivors of other epidemics caused by SARS, Middle East respiratory syndrome (MERS), H1N1A, underscoring the need to recognize the impact of respiratory viral infections on CV health as previously outlined by Xiong et al. 92 in an earlier review.

The high mortality and poor outcomes associated with myocardial injury 93-97 during acute COVID-19 infection have galvanized an interest among research communities to characterize the long-term CV effects of SARS-CoV-2 infection. Insights from both prospective and retrospective studies continue to shape our understanding of its long-term effects. While retrospective studies rely on electronic medical health records and labelled datasets, 7,34,98 prospective studies 19, 22 have innovatively turned to remote (e.g. telemedicine, symptom apps) assessments and face-face reviews.

There is now compelling evidence from large retrospective cohort studies that speak to the rising cases of new cardiac diagnoses. In a study of 73 435 (median age 61 years, 88% men) non-hospitalized patients using the US Department of Veterans Affairs health services, Al-Aly et al. 7 demonstrated a high risk of death and incident CV and metabolic diseases associated with COVID-19 beyond 30 days of infection. A UK-based study of 47 780 hospitalized COVID-19 patients (mean age 65 years, 55% men) demonstrated that a diagnosis of COVID-19 was linked to a three-fold increased risk of major adverse CV events up to 4 months from diagnosis (vs. non-hospitalized controls). In this study, Ayoubkhani et al. 98 further noted that the increased risk was not confined to the older age group and was more pronounced in non-White patients. Daugherty et al., 99 in a related paper, compared the incidence of new cardiometabolic diagnoses in post-COVID-19 patients with two important controls groups-non-COVID-19 controls (from 2019 to 2020) and those recovering from lower respiratory tract infection (LRTI). In their study, COVID-19 was associated with a nearly two-fold increased risk of incident CV diagnoses. However, when comparisons were made with LRTI controls, the excess risk of cardiomyopathy was no longer significant. These findings are in line with another study that used primary healthcare data in the UK (OpenSAFELY platform). Tazare et al. 100 revealed that the excess risk of major adverse CV events among previously hospitalized COVID-19 patients was similar to patients admitted with a diagnosis of pneumonia, although the risk of developing type 2 diabetes was higher after COVID-19.

In the post-acute period, cardiac abnormalities have been reported in several prospective observational studies. A summary of selected studies (n . 50) employing three widely used investigative tools-echocardiography, cardiac magnetic resonance (CMR), and cardiopulmonary exercise test-is provided in Table 1 101, 102, 109, 112, [114] [115] [116] [120] [121] [122] 124, 125, 128, 130, 131, 133, 135 and highlights the vast heterogeneity in the prevalence of abnormalities.

Numerous studies have evaluated the role of 12-lead electrocardiogram (ECG) in screening patients for post-acute cardiac manifestations, 36, 103, 117, 124, 136 although commonly pre-COVID-19 control ECGs are missing. Dynamic ECG changes (e.g. depolarization, repolarization abnormalities, arrhythmias) 137,138 while frequent during acute illness, tend to resolve in the majority of hospitalized patient by 6 months post-acute COVID-19 and are often comparable to risk-factor matched controls. 36, 103, 117, 136 Nevertheless, sinus arrhythmia is frequent in the post-acute phase and manifests as transient or sustained periods of sinus tachycardia or bradycardia. [103] [104] [105] In a study of 234 patients, Radin et al. observed that 13.7% of patients wearing a Fitbit displayed persistently elevated heart rate (.5 beats above the pre-COVID baseline resting heart rate) up to 133 days postinfection. 139 Currently, there are no published studies on the role of prolonged ECG monitoring (Holter) in post-COVID-19 management. Prior studies of post-influenza patients have demonstrated a high burden of atrial 140 and ventricular arrhythmias, which are known to correlate with inflammatory markers. [141] [142] [143] [144] [145] These findings imply that a subset of COVID-19 patients (e.g. with ongoing inflammation) may potentially benefit from ECG monitoring in the long term.

Both transthoracic echocardiography and CMR are cornerstones in the diagnosis of acute and chronic cardiac pathology. 146, 147 Cardiac abnormalities commonly reported on follow-up imaging include myopericarditis, right ventricular dysfunction, and ischaemia/infarction.

Myopericarditis may be suspected clinically based on the presence of one clinical (pericarditic chest pain, heart failure or progression of heart failure symptoms, palpitations, syncope, newonset arrhythmia) and one diagnostic criteria (ECG abnormalities, troponin elevation, wall motion abnormalities on echocardiogram, CMR abnormalities) as per the 2013 European Society of Cardiology (ESC) Position statement 148 and 2020 AHA scientific statement. 149, 150 While endomyocardial biopsy (EMB) is the gold standard investigation for histological evaluation of suspected fulminant cases, [148] [149] [150] CMR remains the best alternative for noninvasive evaluation of stable cases 149, 151 and provides information on several pathological processes including myocardial oedema, hyperaemia, necrosis, and fibrosis by exploiting alterations in fundamental magnetic properties of the tissue (T1 and T2 relaxation). In 2018, the Journal of American College of Cardiology scientific expert panel provided recommendations for updated CMR criteria to improve detection of active myocarditis. 151 This required an increase in at least one T1-based method including T1 mapping (sensitive to hyperaemia, fibrosis, necrosis, and oedema) and one T2-based method including T2 mapping (sensitive to oedema). 151 Although the incorporation of quantitative tissue mapping has augmented the sensitivity of CMR for myocarditis, two limitations exist with such an approach. The first is that CMR diagnostic performance may be impacted by co-morbidities. 152, 153 The second is that readouts of T1 and T2 values of the myocardium are poorly standardized. 154 As a result, combining quantitative CMR data from multiple centres is problematic. In June 2020, a follow-up CMR study of 100 patients (67% nonhospitalized) reported an alarmingly high rate (60%) of persistent myocardial inflammation at 71 days post-infection. 122 At least 22% of patients in this study were found to be co-morbid. Other studies have also reported a high prevalence of CMR abnormalities, though comparator groups were typically healthy making it challenging to rule out confounding effects of co-morbidities such as hypertension and diabetes. In contrast to these early studies, a subsequent study 128 of healthcare workers, which enrolled comorbidity matched controls with mild infection, reported a lower prevalence of CMR abnormalities, with no significant difference in 6-month CMR tissue abnormalities between seropositive and seronegative healthcare workers. Similarly, a study of 1285 UK Biobank participants 155 with pre-and post-SARS-CoV-2 infection imaging revealed no link between prior infection and longitudinal changes in cardiac or aortic phenotypes before and after adjusting for potential confounders including co-morbidities.

There are now abundant studies evaluating the burden of myocarditis among athletes in view of associated risks of sudden cardiac death. The majority was undertaken within 1-2 months of infection 105, 126, 127, 129 and the prevalence of myocarditis on objective testing was found to be generally low (0-3%). Studies evaluating persistent symptom burden among athletes beyond 8 weeks of infection are lacking, though it is likely, given the lower risk profile of athletes (e.g. less likely to be obese and co-morbid), that ongoing symptoms are infrequent in this population.

The role of CMR in elucidating a cause for elevated troponin following acute COVID-19 is less contentious. Several prior studies [156] [157] [158] have confirmed its incremental value in clarifying a diagnosis when the aetiology of troponin elevation is unclear. In a study of 148 troponin-positive patients, Kotecha et al. 101 reported that 26% had myocarditis, 22% had inducible ischaemia/infarction, and 6% had evidence of both.

Echocardiography is vital in the early diagnosis of cardiac pathology in COVID-19 infection (suspected myocarditis, Takotsubo syndrome, myocardial infarction, pericardial effusion, etc.), particularly where haemodynamic stability is uncertain. 69, 159 Right ventricular dilatation and dysfunction are the most common echocardiographic abnormalities with prognostic significance. 125, 160, 161 When the acute infection abates, 161 right ventricular abnormalities improve in most patients. 36, 125 Left ventricular systolic dysfunction is comparatively less frequent. 101, 125 Follow-up echo and CMR studies have confirmed that even among those with severe acute infection 125 or elevated troponin, 101 systolic impairment is rare, affecting up to 9-11% of patients. Concordant with this, in the UK-wide national follow-up study (PHOSP-COVID), levels of N-terminal pro B-type natriuretic peptide (NT-proBNP) were abnormal in only 7% of patients at 5 months post-hospitalization. 19 Unlike systolic dysfunction, abnormalities in diastology may be common (up to 60% of hospitalized patients). 109 The lack of pre-COVID imaging, however, makes it challenging to disaggregate what is cause and effect in patients.

Computed tomography (CT) angiography (CTA) has garnered considerable attention for its ability to detect pulmonary emboli, 162-164 epicardial coronary stenoses, or vascular pathology (e.g. mural thrombus or vasculitis) related to acute SARS-CoV-2 infection. Perivascular fat attenuation index, 165, 166 a biomarker of vascular inflammation on CTA, has shown promise for prognostic risk stratification. In an early study by Kotanidis et al., 167 a new radiotranscriptomic signature of vascular inflammation demonstrated an association between SARS-CoV-2 variant B1.1.7, vascular inflammation, and increased mortality risk. Delayed arterial and venous thrombo-embolic complications [168] [169] [170] have also been reported in the post-acute period. Dual-energy CTA, in a study of 55 patients at 3 months post-infection, detected both proximal arterial thrombosis (5.4%) and distal microangiopathy (65.5%) in a significant proportion of symptomatic patients. 171 Cardiopulmonary exercise testing has shed light on the relevant pathophysiological brakes applied by COVID-19 on exercise capacity. 36, 102, [106] [107] [108] 115, [118] [119] [120] Several studies have demonstrated a reduction in peak oxygen consumption post-acute COVID-19. 36, 102, 106, 115, 120, 172 The predominant mechanism for this finding seems to be muscular deficiencies (impairment in oxygen extraction 173 ), manifesting primarily as submaximal exercise tests or an early anaerobic threshold. Generalized muscle wasting or sarcopenia is also common. 174, 175 Physical inactivity, cytokine storm, poor nutrition, intensive care therapy, mechanical ventilation, and drugs (e.g. dexamethasone) have all been implicated. The ratio of exercise minute ventilation coupled with carbon dioxide output (VE/VCO 2 ), a marker of ventilatory efficiency, may also be abnormal. 36, 102, 120 However, breathing reserve is relatively preserved, arguing against pulmonary factors and supporting hyperventilation or dysfunctional breathing as a potential cause. 172 Heart rate recovery provides a surrogate measure of autonomic health in patients. Following COVID-19, delayed heart rate recovery has been noted in some patients, 36, 176 though the majority recovers spontaneously over time. 36 There are now numerous reports [177] [178] [179] [180] [181] and cohort studies 38 where POTS has been suspected among patients. In a retrospective study of 20 patients 182 referred to a dysautonomia clinic, orthostatic instability on tilt table test or 10 min stand test was observed in 75% of patients. Postural orthostatic tachycardia syndrome was the most common diagnosis in this study, followed by neurocardiogenic syncope (15%) and orthostatic hypotension (10%).

A table summarizing all the relevant cardiac investigations, their advantages, and role in post-COVID management can be found in the Supplementary material online, Table S1 .

Understanding cardiac involvement in the context of multisystem health can provide clues into mechanisms of ongoing injury through recognition of unique patterns of tissue damage (e.g. inflammatory changes or embolic manifestations). In an early study of 58 post-Long COVID/post-acute sequelae of COVID-19 hospitalized COVID-19 patients and 30 matched controls, Raman et al. 120 undertook multiorgan magnetic resonance imaging (MRI) and reported tissue abnormalities involving the lungs (60%), heart (26%), liver (10%), kidneys (29%), and brain (11%) in patients. Magnetic resonance imaging abnormalities in almost every organ correlated with inflammatory markers, suggesting that chronic inflammation could impede recovery. Following on from this work, the PHOSP-COVID study also demonstrated that failure to recover from multiorgan symptoms was associated with markers of persistent inflammation. 19 In another study of 201 patients, Dennis et al. 121 evaluated the prevalence of multiorgan damage among predominantly non-hospitalized patients and noted that symptoms of long COVID clustered among those with multiorgan injury on MRI.

Persistent endothelial dysfunction, 47,183,184 microvascular dysfunction, 101 and prothrombotic tendencies 185 may also contribute to multiorgan dysfunction. 186 Selected studies of advanced imaging modalities including positron emission tomography, CT, and MRI have noted perfusion deficits in the heart and lungs 101,187,188 of COVID-19 survivors at 40-60 days from infection. In one study of hospitalized patients, multiorgan MRI demonstrated evidence of small vessel disease (9.3%) and ischaemic changes (3.7%) in the brain (9.3%) and 1.9% had myocardial infarction 120 2-3 months postinfection. Another study of 104 hospitalized 189 patients observed that inducible myocardial perfusion defects were common among patients with moderate to severe disease but did not differ in burden compared with co-morbidity and risk-factor matched controls. Several studies are currently underway to characterize the burden of vascular and thrombotic complications 190, 191 and to examine the potential benefits of prolonged antithrombotic (extended thromboprophylaxis) and vascular protective therapies (e.g. statins, risk-factor management) in post-acute COVID-19 patients as indicated in Table 2 and Supplementary material online, Table S2 .

Up to a third of patients hospitalized with COVID-19 have a history of chronic CV diseases. 192, 193 Presence of concurrent cardiac disease is typically associated with higher in-hospital mortality, thrombo-embolic risk, and septic shock rates. 97, 194 Even in the post-acute period, patients with a history of heart failure are at a two-to four-fold risk of decompensation and mortality. 195, 196 Increased rates of heart failure exacerbation may present even beyond 30 days after SARS-CoV2 infection. 98 One reason for the rising epidemic of post-discharge heart failure events is the withdrawal of guideline-directed medical therapy during acute illness. 197 Investigators of the TRED-HF study 198 have previously demonstrated the negative impact of heart failure therapy withdrawal in recovered dilated cardiomyopathy patients, resulting in relapse and poor outcomes. The successful resumption and optimization of heart failure therapies 199 may therefore be important in halting heart failure readmissions post-acute COVID-19.

The shared cardiometabolic profile of COVID-19 and cardiac diseases implies that COVID-19 may play a role in destabilizing subclinical diseases (e.g. coronary artery disease and heart failure). This would explain the high prevalence of type 2 myocardial infarction 200 in those with severe COVID-19 and also the rising incidence of 'new' CV diagnoses. 7, 98, 99 Other mechanisms that may contribute include dysregulation of the renin-angiotensin-aldosterone system, 6 endothelial dysfunction, 186, 201, 202 renal injury, 203 and steroid use. 204, 205 Proposed model for investigation and management of cardiovascular sequelae and long COVID Although the true burden of CV pathology post-acute COVID-19 remains elusive, the prevalence of cardiac symptoms in this phase appears high. There is a strong need for evidence in support of cost-effective strategies to exclude significant CV pathology. An approach considered reasonable by some experts [206] [207] [208] involves screening of high-risk individuals for ongoing cardiac involvement including those with abnormal cardiac investigations during the acute phase, new CV diagnosis post-COVID-19, and athletes. Figure 3 shows a possible pragmatic algorithm to guide physicians on the indication for cardiology follow-up and management approaches. Screening of high-risk individuals could comprise of a thorough history, clinical examination, blood test panel (C-reactive protein, troponin, B-type natriuretic peptide/ NT-proBNP, glycated haemoglobin, lipids), ECG, and transthoracic echocardiography at least 8-12 weeks from infection. For patients with clinically significant abnormalities after the screening, additional testing is recommended. Non-invasive tests such as CMR, stress single positron emission computed tomography, Holter, coronary CTA can be considered following screening investigations; invasive coronary angiography or EMB may be indicated for high-risk individuals. Referral to specialist clinics (e.g. POTS, arrhythmia clinic, psychology support) should be considered where relevant. Patients with chronic CV diseases presenting for routine follow-up should be asked about their history of COVID-19 infection and vaccination status. A brief assessment of mental, physical, and cognitive health may be required for selected patients who report ongoing symptoms as this could facilitate early referral to appropriate services (rehabilitation, 209 physiotherapy, 210 psychology, 211 occupational therapy, and social and welfare support) ( Figure 3) and alleviate patient burden.

With regard to return-to-play guidance for athletes, numerous recommendations have been put forward by consensus societies. [212] [213] [214] Although earlier guidelines adopted a conservative approach, recent studies of college and professional athletes have led to a revision 126, 129 in recommendations. Graded resumption to exercise and sports is now considered reasonable for mild infections, whereas exercise restriction for 3 months is still recommended for individuals with suspected myocarditis as per the 2019 position statement from the Sport Cardiology Section of the European Association of Preventive Cardiology. 215 The management of COVID-19-related chronic myocarditis is a subject of considerable debate. In individuals with complicated or tachyarrhythmias), the ESC 148 and AHA 149 recommend EMB for clarification of myocarditis subtype to guide specific treatment options (e.g. immunomodulatory therapy vs. antivirals). 150 Currently, there is no COVID-19 specific guidance on this, though several studies are underway to evaluate the most effective management strategy. The efficacy of oral non-steroidal antiinflammatory drugs and/or colchicine is also being evaluated for COVID-19-associated pericarditis. 216 For the management of post-COVID-19 acute coronary syndromes, patients are typically treated in accordance with the ESC 217 and AHA 218 guidelines released in 2020 and 2014, respectively. Similarly, heart failure management revolves around optimal utilization of contemporaneous therapies as per guidelines. 219, 220 There are currently no published trials on the efficacy of prolonged thromboprophylaxis post-acute COVID-19; however, numerous intervention trials (e.g. HEAL-COVID, 221 STIMULATE ICP) 216 are currently ongoing to address this gap.

After exclusion of significant CV and other organ pathology, the management of long COVID tends to be largely supportive. 222 Given the strong association between obesity and long COVID, measures to reduce weight through caloric restriction, diet, tailored graded exercise, stress reduction, and good sleep hygiene could be beneficial in the long run, 223 with growing evidence indicating its favourable effects on systemic inflammation, 224 vascular dysfunction, 225 and metabolic syndrome. 226 Additionally, a pragmatic approach that is holistic and targeted at alleviating symptoms may also be required. Non-pharmacological approaches including pulmonary rehabilitation, 227 breathing exercise, 228, 229 and alternative therapies 230 (e.g. singing therapy, 231 acupuncture, body rotation, and stretching) have also been suggested to help breathlessness symptoms. Those returning to work may benefit from phased return, allowing individuals with incomplete mental and physical recovery to gradually resume employment. 232 Given that psychosocial factors are a major determinant of incomplete recovery, 38,233 early referral for mental health assessment/cognitive behavioural therapy may benefit some patients.

Postural orthostatic tachycardia syndrome and symptoms of dysautonomia can be debilitating for patients. [178] [179] [180] [181] The management of POTS centres around accurate diagnosis following specialist assessment, correction of reversible causes (dehydration, heat), optimization of chronic disease management, and patient education. In some patients with ongoing palpitations, beta-blockers can be helpful in treating symptoms. 234 Graded exercise programmes 235 encouraging patients to adopt an upright posture may attenuate postural symptoms after prolonged bed rest. Compression pantyhose style stockings with 30-40 mmHg counter pressure may help symptoms of orthostatic hypotension through reduced peripheral venous pooling. 236 In the event that symptoms persist despite compliance with the aforementioned approaches, pharmacological therapies (e.g. ivabradine, fludrocortisone, midodrine, clonidine, and methyldopa 237 ) may be considered.

The vast majority of persistent CV abnormalities following COVID-19 is due to tissue injury sustained during the acute illness. The impact of acute therapies on long-term CV health deserves further investigation. Currently, anti-inflammatory drugs such as dexamethasone 238 and tocilizumab 239 or antivirals such as remdesivir 240 have been identified as key weapons in the therapeutic armamentarium against severe COVID-19. However, the extent to which they affect cardiopulmonary recovery in the long term is still unclear and data regarding cardiac injury rates are not yet widely available. Whether or not ongoing inflammation in long COVID may reflect a rebound phenomenon in dexamethasone-or tocilizumab-treated patients also warrants further study. The complicated role of anticoagulation in patients deserves some consideration. In the acute phase, mounting evidence confirms a lack of benefit of aspirin in reducing mortality among hospitalized 241 and non-hospitalized outpatients. 242 Data in support of therapeutic dose anticoagulation are mixed with the severity of illness (non-critical hospitalized patients benefitting most) being a critical determinant of treatment success. 243 The multiplatform adaptive randomized controlled clinical trial, 244 which combined data from ACTIV-4a, REMAP-CAP, and ATTACC studies, reported an improved survival until hospital discharge and organ support-free days with therapeutic dose heparin in moderately ill patients but not during critical illness. In contrast, other studies (ACTION, 245 INPIRATION, 246 and RAPID trials) 247 reported no difference in primary outcome measures among patients receiving therapeutic vs. prophylactic dose anticoagulation. Investigators of the ACTIV-4B 242 study also reported no improvement in 45-day survival among non-hospitalized patients receiving aspirin, low dose, and high dose apixaban vs. placebo. Further research is therefore needed to better understand the long-term benefits of anticoagulation in patients.

The most effective way of preventing serious complications from SARS-CoV-2 infection is through vaccination. [248] [249] [250] [251] [252] [253] [254] Previous experience with influenza vaccine has taught us to expect a favourable relationship between vaccination and CV outcomes. 255, 256 There are at least eight major SARS-CoV-2 vaccines available globally, with excellent efficacy. Early data from a patient-led observational study 257 has hinted at the possibility of long COVID symptoms being alleviated through vaccination. Of 900 people with long COVID, 56.7% of those vaccinated saw an overall improvement, 18.7% a deterioration, and 24.6% were unchanged post-vaccination. In another survey study (COVID symptom app study), 258,259 the odds of experiencing symptoms more than 28 days post-vaccination was halved by two vaccinations (n = 906). Some experts posit that an accelerated viral clearance and a muted chronic inflammatory response could explain symptom reduction following vaccination. 260 While there is little doubt that early inoculation confers the greatest protection against severe COVID-19, rare cases of vaccine-induced adverse effects have led to a rise in vaccine hesitancy. 261 In particular, two widely available vaccine strategies including mRNA vaccines 250, 262 and vector-based (ChAdOx1 nCov-19 263 and Ad26.COV2.S/Janssen) 251 have been linked to cases of myocarditis [264] [265] [266] and vaccine-induced prothrombotic immune thrombocytopenia (VITT), 267 respectively. Although rare ( 5 per million), VITT due to antibodies to platelet factor 4 typically occurs following a single vaccine dose and may be fatal in some (pulmonary embolus, cerebral venous thrombosis). In contrast, myocarditis, potentially due to an autoimmune response (triggered by molecular mimicry between spike protein and selfantigen), tends to be more common after the second mRNA vaccine dose but is comparatively less life-threatening as the majority of cases spontaneously resolves. [264] [265] [266] Future direction Current evidence for the treatment of long COVID is lacking, though many clinical trials for long COVID and CV sequelae ( Table 2 ) are currently underway. A list of selected clinical trials in long COVID are presented in Supplementary material online, Table S2 to demonstrate the diversity of treatments under investigation. Studies include a variety of rehabilitation programmes (telemedicine and face-face) for treatment of fatigue, cognitive decline and breathlessness, therapies targeted at cognition (e.g. transcranial stimulation), metabolic modulators (e.g. niagen), immunomodulatory therapies (e.g. steroids, laranilubmab, tocilizumab, atorvastatin, colchicine), antifibrotic treatments (e.g. pirfenidone, LYT-100), and anticoagulation (e.g. apixaban). The World Health Organization (see https://clinicaltrials.gov/ct2/who_table or https://www.who.int/ clinical-trials-registry-platform) and ClinicalTrials.gov (see https:// clinicaltrials.gov/ct2/results?cond=COVID-19) list more than 730 studies related to COVID-19; .80 have a major emphasis on longterm CV outcomes. As examples, selected studies with 400 or more participants are listed in Table 3 .

Current priorities for research include (i) establishing the prevalence of persistent or chronic SARS-CoV-2 induced CV injury;

(ii) elucidating causal mechanisms including the role of immune system, obesity, endotheliopathy, and genetic predispositions; (iii) developing an understanding of CV symptom burden (as part of the long COVID spectrum) and its association with pathology; (iv) developing and refining scalable diagnostic methods with high specificity for COVID-19-associated CV complications (including POTS); (v) identifying novel therapeutic solutions or repurposing old drugs that can protect or reverse COVID-19-associated long-term CV injury; (vi) evaluating the role of vaccination and SARS-CoV-2 variants on cardiac injury; (vii) evaluating the long-term impact of SARS-CoV-2 infection on those with pre-existing cardiac diseases and future risk of heart failure, ischaemic events, and arrhythmias; (viii) evaluating the effects of COVID-19-related autonomic dysfunction on CV homeostasis; and (ix) understanding the impact of long COVID on healthcare costs and on working population. 4, 230, 233 A concerning trend observed in recent studies 36, 19, 121, 268 is the marked dissociation seen between symptoms and objective measures of health highlighting the limitations of routine clinical investigations. In this regard, deeper phenotyping efforts including advanced cardiopulmonary imaging (e.g. hyperpolarized xenon 269 ), mass spectrometry, 270 metabolomics, 271 proteomics, 272 whole-genome sequencing, and gut microbiome 273 studies promise to unscramble the Rubix cube of pathophysiological processes that underpin long COVID. It is anticipated that multiple endophenotypes 230, 233 (inflammatory, metabolic, autoimmune, neurocognitive, psychological 233 ) will surface, through artificial intelligence-driven data analysis, enabling precision diagnostics, prognostic risk prediction, and therapeutics for patients.

Long COVID is emerging as a major public health issue. Our current understanding of pathophysiological mechanisms and treatment options remains limited; however, there is great optimism Long COVID/post-acute sequelae of COVID-19

as several national and international research initiatives promise to disentangle the complexities of this disease. The high burden of cardiopulmonary symptoms along with other organ manifestations underscores the need for multispecialty input, 274, 275 a model that is likely to also profit other chronic diseases. Proactive screening and investigation, where appropriate, could allay fears and anxiety among patients. Considerable efforts to find the right balance between cost-effective investigations and benefit to patients are needed to ensure sustainable service provision in these challenging economic times. Finally, the vast inequalities 43, 276 in healthcare provision exposed by COVID-19 will continue to be magnified by long COVID, a problem that calls for global humanitarian efforts to promote and fund equitable access to healthcare, social and welfare support, and vaccines across the world.

Supplementary material is available at European Heart Journal online. is also a nonexecutive director and consultant to Caristo Diagnostics and holds two patents (one granted and one in review) on pericoronary fat assessment for risk prediction. T.F.L. has no conflicts of interest related to this manuscript but received educational and research grants from Abbott, Amgen, AstraZeneca, Boehringer Ingelheim, Daichi-Sankyo, Novartis, Sanofi, Servier, and Vifor outside this field. D.A.B. has no conflicts of interest related to this manuscript but has received consultant fees from Bayer.

An interactive web-based dashboard to track COVID-19 in real time

Long COVID: let patients help define long-lasting COVID symptoms

Why we need to keep using the patient made term "Long Covid

COVID-19 rapid guideline: managing the long-term effects of COVID-19

World Health Organization. A clinical case definition of post COVID-19 condition by a Delphi consensus

Post-acute COVID-19 syndrome

High-dimensional characterization of post-acute sequelae of COVID-19

Confronting our next national health disaster-longhaul Covid

Long covid: how to define it and how to manage it

Post-viral fatigue and COVID-19: lessons from past epidemics

Fallout from the COVID-19 pandemic-should we prepare for a tsunami of post viral depression?

Active Epstein-Barr virus infection in post-viral fatigue syndrome

A role for herpes simplex virus in the aetiology of chronic fatigue syndrome and related disorders

Chronic widespread musculoskeletal pain, fatigue, depression and disordered sleep in chronic post-SARS syndrome; a case-controlled study

Post-Ebolavirus disease syndrome: what do we know?

Attributes and predictors of long COVID

Persistent symptoms following SARS-CoV-2 infection in a random community sample of 508,707 people

Office for National Statistics. Prevalence of ongoing symptoms following coronavirus (COVID-19) infection in the UK

Physical, cognitive, and mental health impacts of COVID-19 after hospitalisation (PHOSP-COVID): a UK multicentre prospective cohort study

Post-COVID syndrome in non-hospitalised patients with COVID-19: a longitudinal prospective cohort study

Persistent symptoms in adult patients one year after COVID-19: a prospective cohort study

6-month consequences of COVID-19 in patients discharged from hospital: a cohort study

1-year outcomes in hospital survivors with COVID-19: a longitudinal cohort study

Post acute sequelae of SARS-CoV-2 infection (PASC)-formally long COVID

Post COVID-19 sequelae: a prospective observational study from Northern India

Clinical predictors of long COVID-19 and phenotypes of mild COVID-19 at a tertiary care centre in India

Post-COVID-19 syndrome among symptomatic COVID-19 patients: a prospective cohort study in a tertiary care center of Bangladesh

Prevalence of long COVID symptoms in Bangladesh: a prospective inception cohort study of COVID-19 survivors

Post-acute effects of SARS-CoV-2 infection in individuals not requiring hospital admission: a Danish population-based cohort study

Surviving COVID-19 in Bergamo province: a post-acute outpatient re-evaluation

Respiratory and psychophysical sequelae among patients with COVID-19 four months after hospital discharge

Sequelae in adults at 6 months after COVID-19 infection

Population-based estimates of post-acute sequelae of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (PASC) prevalence and characteristics

Long COVID in a prospective cohort of home-isolated patients

3-month, 6-month, 9-month, and 12-month respiratory outcomes in patients following COVID-19-related hospitalisation: a prospective study

Symptom persistence despite improvement in cardiopulmonary health-insights from longitudinal CMR, CPET and lung function testing post-COVID-19

Characterizing long COVID in an international cohort: 7 months of symptoms and their impact

Risk factors for long COVID: analyses of 10 longitudinal studies and electronic health records in the UK. medRxiv

Office for National Statistics. Prevalence of ongoing symptoms following coronavirus (COVID-19) infection in the UK

Office for National Statistics. Prevalence of ongoing symptoms following coronavirus (COVID-19) infection in the UK. 11

Global burden of 87 risk factors in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study

Obesity during COVID-19: an underrated pandemic?

Offline: COVID-19 is not a pandemic

National child measurement programme

Heart disease and stroke statistics-2021 update

Persistent endotheliopathy in the pathogenesis of long COVID syndrome

The link between abdominal obesity, metabolic syndrome and cardiovascular disease

Office of National Statistics. The prevalence of long COVID symptoms and COVID-19 complications

Office of National Statistics. Prevalence of ongoing symptoms following coronavirus (COVID-19) infection in the UK

Characteristics of long covid: findings from a social media survey

Chronic fatigue syndrome and long covid: moving beyond the controversy

Persistent symptoms in patients after acute COVID-19

Myalgic encephalomyelitis: international consensus criteria

Myalgic encephalomyelitis/chronic fatigue syndrome: clinical working case definition, diagnostic and treatment protocols

British Thoracic Society survey of rehabilitation to support recovery of the post-COVID-19 population

Neuroinflammation and cytokines in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS): a critical review of research methods

FP03-MO-02 neuropathology of post-infectious chronic fatigue syndrome

Chronic fatigue syndrome from vagus nerve infection: a psychoneuroimmunological hypothesis

Brain imaging before and after COVID-19 in UK Biobank

Dying with SARS-CoV-2 infection-an autopsy study of the first consecutive

Pathological features of COVID-19-associated myocardial injury: a multicentre cardiovascular pathology study

Myocarditis is rare in COVID-19 autopsies: cardiovascular findings across 277 postmortem examinations

Myocarditis: the Dallas criteria

COVID-19: the heart of the matter-pathological changes and a proposed mechanism

A postmortem portrait of the coronavirus disease 2019 (COVID-19) pandemic: a large multi-institutional autopsy survey study

Pathological evidence for SARS-CoV-2 as a cause of myocarditis: JACC review topic of the week

Association of cardiac infection with SARS-CoV-2 in confirmed COVID-19 autopsy cases

Characterization of myocardial injury in patients with COVID-19

COVID-19-associated nonocclusive fibrin microthrombi in the heart

Endothelialitis plays a central role in the pathophysiology of severe COVID-19 and its cardiovascular complications

Role of angiotensin-converting enzyme 2 and pericytes in cardiac complications of COVID-19 infection

The signal pathways and treatment of cytokine storm in COVID-19

Cytokine storm with rapidly elevated interleukin-6 indicates sudden death in patients with critical COVID-19

Viral myocarditis-diagnosis, treatment options, and current controversies

Perivascular adipocytes in vascular disease

Anti-heart antibodies levels and their correlation with clinical symptoms and outcomes in patients with confirmed or suspected diagnosis COVID-19

Diverse functional autoantibodies in patients with COVID-19

High frequency of cerebrospinal fluid autoantibodies in COVID-19 patients with neurological symptoms

Long COVID/post-acute sequelae of COVID-19

Establishing the prevalence of common tissue-specific autoantibodies following severe acute respiratory syndrome coronavirus 2 infection

Autoantibodies to nuclear envelope antigens in chronic fatigue syndrome

Antibodies to β adrenergic and muscarinic cholinergic receptors in patients with Chronic Fatigue Syndrome

Longitudinal immune dynamics of mild COVID-19 define signatures of recovery and persistence

Sustained prothrombotic changes in COVID-19 patients 4 months after hospital discharge

A case of COVID-19 infection with delayed thromboembolic complication on warfarin

Delayed manifestation of COVID-19 presenting as lower extremity multilevel arterial thrombosis: a case report

Late acute pulmonary embolism after mild Coronavirus Disease 2019 (COVID-19): a case series

Pulmonary embolism in hospitalized patients with COVID-19: a multicenter study

COVID-19 patients may become predisposed to pulmonary arterial hypertension

Persistent endothelial dysfunction in post-acute COVID-19 syndrome: a casecontrol study

Vascular alterations among young adults with SARS-CoV-2

Coronaviruses and the cardiovascular system: acute and long-term implications

Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China

Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China

Prevalence and impact of myocardial injury in patients hospitalized with COVID-19 infection

Association of troponin levels with mortality in Italian patients hospitalized with coronavirus disease 2019: results of a multicenter study

Characteristics and clinical significance of myocardial injury in patients with severe coronavirus disease 2019

Post-COVID syndrome in individuals admitted to hospital with COVID-19: retrospective cohort study

Risk of clinical sequelae after the acute phase of SARS-CoV-2 infection: retrospective cohort study

Rates of serious clinical outcomes in survivors of hospitalisation with COVID-19: a descriptive cohort study within the OpenSAFELY platform

Patterns of myocardial injury in recovered troponin-positive COVID-19 patients assessed by cardiovascular magnetic resonance

Assessment of functional capacity with cardiopulmonary exercise testing in non-severe COVID-19 patients at three months follow-up

Cardiac involvement in consecutive elite athletes recovered from Covid-19: a magnetic resonance study

Cardiac involvement in COVID-19 patients: mid-term follow up by cardiovascular magnetic resonance

Cardiac magnetic resonance findings in patients recovered from COVID-19: initial experiences in elite athletes

Cardiopulmonary exercise pattern in patients with persistent dyspnoea after recovery from COVID-19

Cardiopulmonary exercise testing might be helpful for interpretation of impaired pulmonary function in recovered COVID-19 patients

Cardiopulmonary exercise testing to assess persistent symptoms at 6 months in people with COVID-19 who survived hospitalization: a pilot study

Cardiopulmonary recovery after COVID-19: an observational prospective multicentre trial

Cardiovascular evaluation after COVID-19 in 137 collegiate athletes: results of an algorithm-guided screening

Cardiovascular magnetic resonance findings in competitive athletes recovering from COVID-19 infection

Cardiovascular sequalae in uncomplicated COVID-19 survivors

COVID-19 myocardial pathology evaluation in athletes with cardiac magnetic resonance (COMPETE CMR)

COVID-19: myocardial injury in survivors

Deconditioning as main mechanism of impaired exercise response in COVID-19 survivors

Echocardiographic comparison of COVID-19 patients with or without prior biochemical evidence of cardiac injury after recovery

Evaluation for myocarditis in competitive student athletes recovering from coronavirus disease 2019 with cardiac magnetic resonance imaging

Hyperventilation: a possible explanation for long-lasting exercise intolerance in mild Covid-19 survivors?

Impact of COVID-19 on exercise pathophysiology: a combined cardiopulmonary and echocardiographic exercise study

Medium-term effects of SARS-CoV-2 infection on multiple vital organs, exercise capacity, cognition, quality of life and mental health, post-hospital discharge

Multiorgan impairment in low-risk individuals with post-COVID-19 syndrome: a prospective, community-based study

Outcomes of cardiovascular magnetic resonance imaging in patients recently recovered from coronavirus disease 2019 (COVID-19)

Patients recovered from COVID-19 show ongoing subclinical myocarditis as revealed by cardiac magnetic resonance imaging

Pericarditis and myocarditis long after SARS-CoV-2 infection: a crosssectional descriptive study in health-care workers

Persisting adverse ventricular remodeling in COVID-19 survivors: a longitudinal echocardiographic study

Prevalence of clinical and subclinical myocarditis in competitive athletes with recent SARS-CoV-2 infection: results from the big ten COVID-19 cardiac registry

Prevalence of inflammatory heart disease among professional athletes with prior COVID-19 infection who received systematic return-to-play cardiac screening

Prospective case-control study of cardiovascular abnormalities 6 months following mild COVID-19 in healthcare workers

SARS-CoV-2 cardiac involvement in young competitive athletes

Short-term cardiac outcome in survivors of COVID-19: a systematic study after hospital discharge

Short-term outpatient follow-up of COVID-19 patients: a multidisciplinary approach

Six months follow-up of patients with invasive mechanical ventilation due to COVID-19 related ARDS

Cardiac pathology 6 months after hospitalization for COVID-19 and association with the acute disease severity: cardiac MRI 6 months after COVID-19

Cardiac involvement in patients recovered from COVID-2019 identified using magnetic resonance imaging

Identifying patients at risk of post-discharge complications related to COVID-19 infection

Elevated extracellular volume fraction and reduced global longitudinal strains in patients recovered from COVID-19 without clinical cardiac findings

Electrocardiographic manifestations of COVID-19

Management of arrhythmias associated with COVID-19

Assessment of prolonged physiological and behavioral changes associated with COVID-19 infection

The association between influenza infection, vaccination, and atrial fibrillation: a nationwide case-control study

C-reactive protein elevation in patients with atrial arrhythmias: inflammatory mechanisms and persistence of atrial fibrillation

Inhibition of soluble TNFα prevents adverse atrial remodeling and atrial arrhythmia susceptibility induced in mice by endurance exercise

Inflammation and the pathogenesis of atrial fibrillation

Source of inflammatory markers in patients with atrial fibrillation

Higher high-sensitivity c reactive protein is associated with future premature ventricular contraction: a community based prospective cohort study

Cardiac imaging to evaluate left ventricular diastolic function

Cardiovascular magnetic resonance

Current diagnostic and treatment strategies for specific dilated cardiomyopathies: a scientific statement from the American Heart Association

Management of acute myocarditis and chronic inflammatory cardiomyopathy: an expert consensus document

Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases

Cardiovascular magnetic resonance in nonischemic myocardial inflammation: expert recommendations

T1 mapping in discrimination of hypertrophic phenotypes: hypertensive heart disease and hypertrophic cardiomyopathy: findings from the international T1 multicenter cardiovascular magnetic resonance study

Myocardial native T2 measurement to differentiate light-chain and transthyretin cardiac amyloidosis and assess prognosis

Standardized image interpretation and post processing in cardiovascular magnetic resonance: Society for Cardiovascular Magnetic Resonance (SCMR) board of trustees task force on standardized post processing

Longitudinal changes of cardiac and aortic imaging phenotypes following COVID-19 in the UK biobank cohort

Troponin-positive chest pain with unobstructed coronary arteries: incremental diagnostic value of cardiovascular magnetic resonance imaging

Prognostic role of CMR and conventional risk factors in myocardial infarction with nonobstructed coronary arteries

The role of cardiovascular magnetic resonance in patients presenting with chest pain, raised troponin, and unobstructed coronary arteries

Global evaluation of echocardiography in patients with COVID-19

Right ventricular dilation in hospitalized patients with COVID-19 infection

Prognostic utility of right ventricular remodeling over conventional risk stratification in patients with COVID-19

COVID-19 related thrombi in ascending and descending thoracic aorta with peripheral embolization: a case report

Aortic thrombosis in the course of Covid-19 disease; two rare cases

Aortic thrombus in patients with severe COVID-19: review of three cases

Non-invasive detection of coronary inflammation using computed tomography and prediction of residual cardiovascular risk (the CRISP CT study): a post-hoc analysis of prospective outcome data

Association of biologic therapy with coronary inflammation in patients with psoriasis as assessed by perivascular fat attenuation index

Radiotranscriptomic analysis of perivascular adipose tissue quantifies vascular inflammation in Covid-19 from routine CT angiograms: stratification of "new UK variant" infection and prediction of in-hospital outcomes

Delayed catastrophic thrombotic events in young and asymptomatic post COVID-19 patients

Postdischarge thrombosis and hemorrhage in patients with COVID-19

Incidence of venous thromboembolism in patients discharged after COVID-19 hospitalisation

Assessment of pulmonary arterial circulation 3 months after hospitalization for SARS-CoV-2 pneumonia: dual-energy CT (DECT) angiographic study in 55 patients

Use of cardiopulmonary stress testing for patients with unexplained dyspnea post-coronavirus disease

Persistent exertional intolerance after COVID-19: insights from invasive cardiopulmonary exercise testing

COVID-19 is associated with clinically significant weight loss and risk of malnutrition, independent of hospitalisation: a post-hoc analysis of a prospective cohort study

COVID-19: a major cause of cachexia and sarcopenia?

Importance of cardiopulmonary exercise testing amongst subjects recovering from COVID-19

Long-Haul post-COVID-19 symptoms presenting as a variant of postural orthostatic tachycardia syndrome: the Swedish experience

Autonomic dysfunction in 'long COVID': rationale, physiology and management strategies

New-onset postural orthostatic tachycardia syndrome following coronavirus disease 2019 infection

A case report of postural tachycardia syndrome after COVID-19

Acute hyperhidrosis and postural tachycardia in a COVID-19 patient

Postural orthostatic tachycardia syndrome (POTS) and other autonomic disorders after COVID-19 infection: a case series of 20 patients

Convalescent COVID-19 patients are susceptible to endothelial dysfunction due to persistent immune activation

Update on endothelial dysfunction in COVID-19: severe disease, long COVID-19 and pediatric characteristics

Thromboembolic risk in hospitalised and non-hospitalised COVID-19 patients: a self-controlled case series analysis of a nation-wide cohort

COVID-19 is, in the end, an endothelial disease

Lung perfusion SPECT/CT imaging in post COVID-19 pneumonia: the spectrum of imaging findings

Preliminary detection of lung hypoperfusion in discharged Covid-19 patients during recovery

Myocardial perfusion after COVID-19 infection: no persisting impaired myocardial blood flow in surviving patients

The chief scientist office cardiovascular and pulmonary imaging in SARS coronavirus disease-19 (CISCO-19) study

Incidence of thrombotic complications in hospitalised and non-hospitalised patients after COVID-19 diagnosis

Characterisation of in-hospital complications associated with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol UK: a prospective, multicentre cohort study

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

Characteristics and outcomes of patients hospitalized for COVID-19 and cardiac disease in Northern Italy

Prognostic impact of prior heart failure in patients hospitalized with COVID-19

The effect of concomitant COVID-19 infection on outcomes in patients hospitalized with heart failure

Heart failure in COVID-19 patients: prevalence, incidence and prognostic implications

Withdrawal of pharmacological treatment for heart failure in patients with recovered dilated cardiomyopathy (TRED-HF): an open-label, pilot, randomised trial

Optimising heart failure therapies in the acute setting

Cardiac troponin for the diagnosis and riskstratification of myocardial injury in COVID-19: JACC review topic of the week

Endothelial cell infection and endotheliitis in COVID-19

Endothelial dysfunction in COVID-19: a position paper of the ESC working group for atherosclerosis and vascular biology, and the ESC council of basic cardiovascular science

Outcomes for patients with COVID-19 and acute kidney injury: a systematic review and meta-analysis

Evidence for an unidentified ACTH-induced steroid hormone causing hypertension

Volume-dependent essential and steroid hypertension

Screening of potential cardiac involvement in competitive athletes recovering from COVID-19

Post-acute COVID-19 syndrome and the cardiovascular system: what is known?

COVID-19 cardiac injury: implications for long-term surveillance and outcomes in survivors

Early experiences of rehabilitation for individuals post-COVID to improve fatigue, breathlessness exercise capacity and cognition-a cohort study

Physiotherapy management for COVID-19 in the acute hospital setting: clinical practice recommendations

The high mental health burden of "Long COVID" and its association with on-going physical and respiratory symptoms in all adults discharged from hospital

Exercise in the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) era: a question and answer session with the experts endorsed by the section of sports cardiology & exercise of the European Association of Preventive Cardiology (EAPC)

Return-to-play guidelines for athletes after COVID-19 infection

Graduated return to play guidance following COVID-19 infection

Recommendations for participation in competitive and leisure time sport in athletes with cardiomyopathies, myocarditis, and pericarditis: position statement of the Sport Cardiology Section of the European Association of Preventive Cardiology (EAPC)

Long Covid: UCL leads £8m studies into treatments and diagnosis

2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the task force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC)

AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes

Advanced heart failure: a position statement of the heart failure association of the European Society of Cardiology

ACC/AHA/HFSA focused update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America

HElping Alleviate the Longer-term Consequences of COVID-19 (HEAL-COVID) (HEAL-COVID) 2021

Management of postacute Covid-19 in primary care

Benefits of massive weight loss on symptoms, systemic inflammation and cartilage turnover in obese patients with knee osteoarthritis

Chronic inflammation in obesity and the metabolic syndrome

Adipose tissue and vascular dysfunction

Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin

Benefits of pulmonary rehabilitation in COVID-19: a prospective observational cohort study

Rehabilitation of post-COVID-19 patients

Breathing exercises for dysfunctional breathing/hyperventilation syndrome in adults

Long covid-mechanisms, risk factors, and management

Singing teaching as a therapy for chronic respiratory disease-a randomised controlled trial and qualitative evaluation

Ten considerations for effectively managing the COVID-19 transition

Low-dose propranolol and exercise capacity in postural tachycardia syndrome. A randomized study

Deconditioning in patients with orthostatic intolerance

Lower limb and abdominal compression bandages prevent progressive orthostatic hypotension in elderly persons: a randomized single-blind controlled study

Orthostatic hypotension

Dexamethasone in hospitalized patients with Covid-19

Efficacy of tocilizumab in patients hospitalized with Covid-19

Remdesivir for the treatment of Covid-19-final report

Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Effect of antithrombotic therapy on clinical outcomes in outpatients with clinically stable symptomatic COVID-19: the ACTIV-4B randomized clinical trial

ACTIV-4a Investigators

Therapeutic anticoagulation with heparin in critically ill patients with Covid-19

Therapeutic anticoagulation with heparin in noncritically Ill patients with Covid-19

Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an openlabel, multicentre, randomised, controlled trial

Effect of inter-mediate-dose vs standard-dose prophylactic anticoagulation on thrombotic events, extracorporeal membrane oxygenation treatment, or mortality among patients with COVID-19 admitted to the intensive care unit: the INSPIRATION randomized clinical trial

Heparin for moderately Ill patients with Covid-19. medRxiv 2021

Comparative systematic review and meta-analysis of reactogenicity, immunogenicity and efficacy of vaccines against SARS-CoV-2

Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine

Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data

Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19

Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia

Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey

Efficacy of NVX-CoV2373 Covid-19 vaccine against the B.1.351 variant

Association between influenza vaccination and cardiovascular outcomes in high-risk patients: a meta-analysis

Influenza vaccination and major adverse vascular events in high-risk patients

The impact of COVID vaccination on symptoms of long COVID. An international survey of people with lived experience of long COVID

Post-vaccination SARS-CoV-2 infection: risk factors and illness profile in a prospective, observational community-based case-control study

Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, casecontrol study

Initial report of decreased SARS-CoV-2 viral load after inoculation with the BNT162b2 vaccine

Long COVID/post-acute sequelae of COVID-19

Psychological characteristics associated with COVID-19 vaccine hesitancy and resistance in Ireland and the United Kingdom

Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial

Myocarditis after BNT162b2 and mRNA-1273 vaccination

Patients with acute myocarditis following mRNA COVID-19 vaccination

Myocarditis with COVID-19 mRNA vaccines

Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination

Pulmonary function impairment of asymptomatic and persistently symptomatic patients 4 months after COVID-19 according to disease severity

Hyperpolarized 129 Xe MRI abnormalities in dyspneic participants 3 months after COVID-19 pneumonia: preliminary results

Persistent clotting protein pathology in long COVID/post-acute sequelae of COVID-19 (PASC) is accompanied by increased levels of antiplasmin

Serum metabolic profile in patients with long-Covid (PASC) syndrome: clinical implications

Longitudinal proteomic analysis of severe COVID-19 reveals survival-associated signatures, tissue-specific cell death, and cell-cell interactions

Reduced diversity and altered composition of the gut microbiome in individuals with myalgic encephalomyelitis/chronic fatigue syndrome

Fresh evidence of the scale and scope of long covid

Long COVID: tackling a multifaceted condition requires a multidisciplinary approach

Five priorities for universal COVID-19 vaccination